Please login or register to print this page.

ARTICLE CONTRIBUTORS

Joanne Bullen
Email

KEY WORDS

Clinical Articles, Lead Article

Improvements in AF symptoms with catheter ablation

According to data recently published in Circulation: Cardiovascular Quality and Outcomes [1], patients with atrial fibrillation, who were treated with catheter ablation using the NAVISTAR® THERMOCOOL® Catheter, reported markedly fewer symptoms and substantially improved quality of life than patients treated with antiarrhythmic drugs at one year.

The primary study data published in JAMA in January, 2010 demonstrated that at one year, 66% of patients treated with catheter ablation remained free from documented symptomatic AF, compared to 16% of patients treated with medical therapy (95% CI: 0.19, 0.47; P < .001)

A sub-study analysis published on 17th November 2010 in Circulation: Cardiovascular Quality and Outcomes [1], demonstrates that quality of life scores that were 10-20% below population norms, as measured by a commonly used health survey called the Medical Outcomes Study Short Form-36 (SF-36), returned to population norms for patients treated with ablation, but did not change with drugs.

Additionally, symptom frequency and severity scores, measured using the AF Symptom Checklist, decreased by greater than 50% in the ablation group, but were unchanged in the drug group.

“An in-depth analysis of the trial’s data revealed that, for the population studied, 9 of 10 specific measures of quality of life and symptom burden – all except bodily pain – were superior in the group treated with catheter ablation, compared to the drug group,” said Matthew Reynolds, MD, MSc, primary investigator for the sub-study and lead author, and Medical Director of the Economics and Quality of Life Assessment Group at the Harvard Clinical Research Institute in Boston.  “These differences persisted for the duration of the trial and were strongly associated with recurrent arrhythmias, which were much more frequent in the antiarrhythmic drug group.
These results add to a growing body of literature demonstrating that catheter ablation improves quality of life more than antiarrhythmic drugs in appropriately selected patients.”

“The results of this study provide important information for patients with AF and their physicians because it demonstrates that effective treatment of AF through an intervention like ablation can reduce the severity of their symptoms and improve the quality of their life,” said Dr. Reynolds.

In 2006, medical societies including the American Heart Association, American College of Cardiology and the European Society of Cardiology recommended catheter ablation as second-line therapy for AF.

References

  • M.R. Reynolds et al, Improvements in Symptoms and Quality of Life in Patients With Paroxysmal Atrial Fibrillation Treated With Radiofrequency Catheter Ablation Versus Antiarrhythmic Drugs, Circulation: Cardiovascular Quality and Outcomes. (2010; 3: 615-623)

Published on: December 9, 2010

Members Area

Log in or Register now.

 For healthcare professionals only
Anticoagulation sky

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.